This company is no longer active
Sesen Bio Past Earnings Performance
Past criteria checks 0/6
Key information
18.70%
Earnings growth rate
38.66%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 75.14% |
| Return on equity | -12.57% |
| Net Margin | -49.71% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Revenue & Expenses Breakdown
How Sesen Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 40 | -20 | 40 | 37 |
| 30 Sep 22 | 60 | -3 | 41 | 19 |
| 30 Jun 22 | 20 | 48 | 42 | 0 |
| 31 Mar 22 | 22 | 54 | 33 | 0 |
| 31 Dec 21 | 27 | 0 | 29 | 24 |
| 30 Sep 21 | 7 | -24 | 24 | 18 |
| 30 Jun 21 | 18 | -118 | 20 | 0 |
| 31 Mar 21 | 16 | -119 | 16 | 0 |
| 31 Dec 20 | 11 | -23 | 14 | 29 |
| 30 Sep 20 | 11 | -41 | 14 | 0 |
| 30 Jun 20 | 0 | -32 | 13 | 0 |
| 31 Mar 20 | 0 | -60 | 13 | 0 |
| 31 Dec 19 | 0 | -107 | 12 | 0 |
| 30 Sep 19 | 0 | -81 | 12 | 0 |
| 30 Jun 19 | 0 | -82 | 13 | 0 |
| 31 Mar 19 | 0 | -36 | 13 | 0 |
| 31 Dec 18 | 0 | -34 | 12 | 0 |
| 30 Sep 18 | 0 | -33 | 10 | 0 |
| 30 Jun 18 | 0 | -29 | 8 | 0 |
| 31 Mar 18 | 0 | -27 | 8 | 0 |
| 31 Dec 17 | 0 | -29 | 8 | 0 |
| 30 Sep 17 | 1 | -26 | 6 | 0 |
| 30 Jun 17 | 30 | 3 | 10 | 0 |
| 31 Mar 17 | 30 | 3 | 12 | 0 |
| 31 Dec 16 | 30 | 2 | 11 | 0 |
| 30 Sep 16 | 30 | -5 | 14 | 0 |
| 30 Jun 16 | 1 | -34 | 11 | 0 |
| 31 Mar 16 | 1 | -35 | 9 | 0 |
Quality Earnings: SESN is currently unprofitable.
Growing Profit Margin: SESN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SESN is unprofitable, but has reduced losses over the past 5 years at a rate of 18.7% per year.
Accelerating Growth: Unable to compare SESN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SESN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
Return on Equity
High ROE: SESN has a negative Return on Equity (-12.57%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/08 22:58 |
| End of Day Share Price | 2023/03/07 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sesen Bio, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |